Origin Asset Management’s Pfizer PFE Stock Holding History

Origin Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-229,350	Closed	-$7.07M	–	151
2016 Q4	$7.07M	Sell	229,350 -5,692	-2%	-$174K	0.47%	74
2016 Q3	$7.55M	Buy	+235,042	New	+$7.86M	0.48%	71
2013 Q4	–	Sell	-222,394	Closed	-$6.06M	–	108
2013 Q3	$6.06M	Hold	222,394	–	–	0.45%	77
2013 Q2	$5.91M	Buy	+222,394	New	+$6.14M	0.51%	70

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Origin Asset Management's PFE Position: Q1 2017 in Review

Origin Asset Management sold out of Pfizer (PFE) in Q1 2017, closing a stake of 229,350 shares — an estimated $7.07M sold.

Origin Asset Management first reported a position in PFE in Q2 2013 and held it in 4 quarters. The position peaked at $7.55M in Q3 2016. 2,074 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

Origin Asset Management reported no remaining Pfizer position as of Q1 2017 after selling out during the quarter.
Origin Asset Management sold 229,350 Pfizer shares in Q1 2017, an estimated $7.07M.
Origin Asset Management first reported a position in Pfizer in Q2 2013 and held it in 4 quarters.
Origin Asset Management's Pfizer position peaked at $7.55M in Q3 2016.
2,074 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Origin Asset Management's 13F filing for Q1 2017, filed 11 May 2017.